Holen Sie sich die Stockscreener-App
8.10
0.00%
0.00
Schlusskurs vom Vortag:
$8.10
Offen:
$8.02
24-Stunden-Volumen:
36,379
Relative Volume:
0.31
Marktkapitalisierung:
$75.72M
Einnahmen:
$24.99M
Nettoeinkommen (Verlust:
$-108.83M
KGV:
-0.539
EPS:
-15.0286
Netto-Cashflow:
$-91.62M
1W Leistung:
+7.28%
1M Leistung:
+8.00%
6M Leistung:
+7.71%
1J Leistung:
-24.33%
1-Tages-Spanne:
$8.02
$8.15
1-Wochen-Bereich:
$7.4416
$8.3694
52-Wochen-Spanne:
$6.01
$17.44
Adicet Bio Inc Stock (ACET) Company Profile
Firmenname
Adicet Bio Inc
Sektor
Branche
Telefon
617-482-2333
Adresse
131 DARTMOUTH STREET, BOSTON
Compare ACET vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACET
Adicet Bio Inc
|
8.10 | 75.72M | 24.99M | -108.83M | -91.62M | -15.03 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Adicet Bio Inc Stock (ACET) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-30 | Fortgesetzt | Guggenheim | Buy |
| 2024-09-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-06-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-06-27 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-06-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-03-31 | Eingeleitet | SMBC Nikko | Outperform |
| 2022-03-08 | Eingeleitet | Truist | Buy |
| 2022-03-04 | Eingeleitet | Jefferies | Buy |
| 2021-05-18 | Eingeleitet | BTIG Research | Buy |
| 2021-04-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-14 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-04-08 | Eingeleitet | Guggenheim | Buy |
| 2020-11-04 | Eingeleitet | B. Riley Securities | Buy |
| 2020-10-27 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-10-16 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Adicet Bio Inc Aktie (ACET) Neueste Nachrichten
Adicet Bio Stockholders Back Directors, Pay and Auditor - TipRanks
Adicet Bio (ACET) investors back board nominees, pay and KPMG at 2026 meeting - Stock Titan
Adicet Bio Inc (ACET) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Adicet Bio Inc (ACET) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Adicet Bio Inc (ACET) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Adicet Bio Inc (ACET) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Adicet Bio Inc (ACET) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Adicet Bio Inc (ACET) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Adicet Bio Inc (ACET) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Adicet Bio Inc (ACET) Valuation: PE, PB & Fair Value Analysis - TradingKey
Adicet Bio Inc (ACET) Institutional Confidence - TradingKey
ACET: All proposals, including director elections and auditor ratification, were approved by stockholders - TradingView
10 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Adicet Bio Inc. (ACET) Q1 2026 Earnings: Narrowed Loss Beats Street on Cost Discipline, Pipeline ProgressEBITDA Estimate Trend - newsline.com
Adicet Bio teases autoimmune data catalysts, PSMA plans at Jefferies conference - MSN
ACET Q1 2026 Earnings: Better-than-Expected Losses Lift SharesAdjusted Earnings Analysis - newsline.com
Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight - GlobeNewswire Inc.
BPAS - FinancialContent
Adicet Bio Teases Autoimmune Data Catalysts, PSMA Plans at Jefferies Conference - sharewise.com
Adicet Bio (ACET) Slips Nearly 6% as Shares Test Key Support LevelsLong Short Pair - newsline.com
Adicet Bio Inc. (ACET) Surges 7.75% as Bullish Momentum BuildsDividend Arbitrage - The Legal Advocate
Are medical stocks lagging Adicet Bio (ACET) this year? - MSN
ACET Q1 2026 Earnings: Wider Loss Narrows, Stock Holds SteadyEarnings Risk Report - newsline.com
Are Medical Stocks Lagging Adicet Bio (ACET) This Year? - Yahoo Finance
Adicet Bio (ACET) Edges Higher: Modest Gain Amid Key Support and Resistance LevelsBollinger Band - The Legal Advocate
Wall Street Analysts Believe Adicet Bio (ACET) Could Rally 319.64%: Here's is How to Trade - Yahoo Finance
Adicet Bio Shares Halted Ahead of Data Readout That May Steer ACET - Bez Kabli
Adicet Bio (ACET) Shows Resilient Move, Testing Key Resistance After 3.4% GainVerified Analyst Reports - Newser
ACET Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Market ResponsePreliminary Results - newsline.com
Adicet Bio (ACET) Q1 2026 Earnings: EPS $-1.88 Beats EstimatesRevenue Beat Analysis - Newser
Adicet Bio, Inc. 2025 10-K/A Annual Report: Controls, Procedures & Internal Control Certifications - Minichart
Adicet Bio (ACET) updates 10-K to confirm effective 2025 controls - Stock Titan
ACET Stock Chart | ADICET BIO INC (NASDAQ:ACET) - ChartMill
Adicet Bio (ACET) Falls -2.34% — Watching $7.12 Support 2026-05-18Total Put Call - newsline.com
Adicet Bio (ACET) price target decreased by 34.28% to 35.53 - MSN
[SCHEDULE 13G/A] Adicet Bio, Inc. Amended Passive Investment Disclosure - Stock Titan
TradingKey - TradingKey
Adicet Bio CEO to discuss cell therapies at Jefferies health conference - Stock Titan
JonesTrading Initiates Adicet Bio(ACET.US) With Buy Rating, Announces Target Price $20 - Moomoo
Press Release Service: Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates - CRISPR Medicine News
CCORF Maintains Adicet Bio(ACET.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Adicet Bio (NASDAQ: ACET) cuts Q1 2026 loss while advancing prula-cel and ADI-212 pipeline - Stock Titan
Adicet Bio (Nasdaq: ACET) trims Q1 loss and details prula-cel, ADI-212 plans - Stock Titan
Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates - New Castle News
Lupus, arthritis and prostate cancer: new cell trials planned by Adicet Bio - Stock Titan
ACET Stock Price, Quote & Chart | ADICET BIO INC (NASDAQ:ACET) - ChartMill
Finanzdaten der Adicet Bio Inc-Aktie (ACET)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):